• Fatma E Hassan, Hader I Sakr, Passant M Mohie, Howayda Saeed Suliman, Ayman Saber Mohamed, Mohamed H Attia, and Dalia M Eid.
• Department of Medical Physiology, Faculty of Medicine, Cairo University, Egypt.
• Ann. Med. 2021 Dec 1; 53 (1): 103210401032-1040.

BackgroundFibromyalgia (FM) is characterized by musculoskeletal pain, fatigue, sleep and memory disturbance. There is no definitive cure yet for FM-related health problems. Peroxisome proliferator-activated receptor's (PPAR's) activation is associated with insulin sensitisation and improved glucose metabolism. PPAR-γ was reported to alleviate FM allodynia. Limited data are discussing its effect on motor disorders.ObjectiveTo investigate the potential effect of PPAR-γ agonists (pioglitazone, as one member of thiazolidinediones (TZD)) on motor dysfunction in reserpine-induced FM in a rat model.Materials And MethodsThirty-six male Wistar rats were divided into negative control (n = 9) and reserpine-induced FM (n = 27) groups. The latter was subdivided into three equal subgroups (n = 9), positive control (untreated FM model), pioglitazone-treated and GW9662-treated. We evaluated muscle functions and activity of chloramphenicol acetyltransferase, superoxide dismutase, malondialdehyde, and serum levels of interleukin-8 and monocyte chemoattractant protein-1.ResultsPioglitazone significantly relieved fatigue, improved muscle performance, reduced inflammatory cytokines and enhanced antioxidant's activity, while GW9662, a known PPAR-γ antagonist, aggravated the FM manifestations in the rat model.ConclusionPPAR-γ agonists show a promising role against FM-associated motor dysfunctions.

24 keywords...

hide…